Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02023333 · ClinicalTrials.gov registry record · Phase 2
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
A Phase 2 study of Metastatic Colorectal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 7
- Study locations
NCT02023333 is a Phase 2 study of Metastatic Colorectal Adenocarcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants, below the 87-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT02023333, a Phase 2 study of Metastatic Colorectal Adenocarcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the good and bad effects when regorafenib is used instead of standard combination chemotherapy. It is not known if taking regorafenib versus standard chemotherapy will have better, worse or the same results.
Conditions Studied
Interventions
- DRUG Regorafenib
Study Locations (7)
New York
- Downstate Medical Center - Brooklyn
- Memorial Sloan Kettering Cancer Center at Commack - Commack
- Queens Cancer Center of Queens Hospital - Jamaica
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center at Mercy Medical Center - Rockville Centre
- Memorial Sloan Kettering Cancer Center Sleepy Hollow - Sleepy Hollow
New Jersey
- Memorial Sloan Kettering Cancer Center at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-12-10 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02023333
The ClinicalTrials.gov registry entry for NCT02023333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Regorafenib is the first listed.
NCT02023333 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02023333 about?
NCT02023333 is a clinical study titled "Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma". The purpose of this study is to evaluate the good and bad effects when regorafenib is used instead of standard combination chemotherapy. It is not known if taking regorafenib versus standard chemotherapy will have better, worse or the same results.
What is the current status of trial NCT02023333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2013-12-10. Estimated completion is 2025-08-26.
What conditions does trial NCT02023333 study?
This clinical trial studies the following conditions: Metastatic Colorectal Adenocarcinoma.
What interventions are being tested in trial NCT02023333?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02023333?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02023333 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.